When Bladder Cancer Comes Back: Recurrence Questions

Bladder cancer behaves differently from most cancers after treatment. New tumors are common enough that surveillance is built into standard care from the first diagnosis.

NCI's clinical summary puts a number on it. In a series of people with Ta or T1 tumors followed for at least 20 years or until death, the risk of a bladder cancer recurrence after the first resection was 80%.

That number is not a prediction about you. It does explain why your team schedules repeat cystoscopies rather than discharging you.

Two explanations compete in the literature. One is a field defect. Genetic changes are spread widely across the bladder lining, so new tumors arise in new places. The other is reimplantation. Cells loosened during resection settle elsewhere in the lining. One piece of evidence favors the second. Tumors recur downstream more often than upstream.

Recurrence and progression are different events, and teams weigh them differently.

Recurrence means a new tumor of the same kind. Progression means the cancer has moved into the muscle wall or beyond. NCI states that progression is rare for low-grade tumors and common among high-grade cancers.

So the useful question is not only "has it come back." It is:

• Is this recurrence the same grade and stage as before, or higher?
• Has it invaded the muscle layer?
• What did the pathology say about carcinoma in situ?

This section carries an unusual admission from NCI, and knowing it helps you interpret your own schedule.

Surveillance after bladder cancer is standard practice. But NCI notes something rarely said out loud. No trials have tested whether surveillance changes rates of progression, survival, or quality of life. And no trial has defined the best surveillance schedule.

That does not make surveillance pointless. It means your interval rests on judgment and risk grouping, not on trial evidence. Asking how yours was chosen is fair.

Two technical points are settled, though:

• Cystoscopy is the test. NCI states that CT scans and ultrasound do not have enough sensitivity to detect bladder cancers.
• The upper tract needs checking too. Imaging of the kidneys and ureters is essential for staging and surveillance. Four methods are used. Ureteroscopy. Retrograde pyelograms during cystoscopy. Intravenous pyelograms. Or CT urograms.

Ask which of those your follow-up includes, and how often. Ask specifically whether your upper urinary tract is being imaged, not just your bladder.

NCI names the features that mark higher risk of recurrence and of developing invasive cancer. Superficial tumors are more concerning when they are:

• Less differentiated, meaning higher grade.
• Large.
• Multiple.
• Accompanied by carcinoma in situ elsewhere in the bladder lining.

People with these features are described as having the whole urothelial surface at risk. Ask which of these apply to your pathology, because they drive both the schedule and the treatment offered.

For a recurrence that has not reached the muscle, NCI describes a set of options rather than one route everybody takes. Which parts apply to you turns on grade and stage, whether carcinoma in situ is present, how soon after the last resection the tumor appeared, what you have already had, and what your bladder and general health will tolerate.

• Transurethral resection with fulguration, which is removal and cauterizing through a scope, is the usual starting point.
• A single instillation of chemotherapy into the bladder soon after that procedure is used in selected people. It is held back when the bladder wall may have been breached during resection, among other reasons.
• Instillations of bacillus Calmette-Guérin, known as BCG, an immune-activating treatment given into the bladder, are directed at tumors judged to be at intermediate or high risk of progressing. For that group NCI describes a minimum of one year of BCG alongside surveillance. BCG is not the answer for every recurrence, and it is avoided in some people, including those whose immune system is suppressed or who have a traumatic catheterization or active urinary infection at the time.

Ask your urologist which risk group your pathology puts you in, because that is what decides the sequence.

Worth asking:

• Did I get the immediate post-procedure instillation, and if not, why not?
• How long is my BCG course, and what happens at the end of it?
• What would count as BCG not working?

NCI names the group that should consider radical cystectomy. It is people at high risk of progression. Typically that means recurrent high-grade tumors with carcinoma in situ after BCG. Two other risk factors are named: multiple tumors, and tumors larger than 3 cm.

One finding is worth carrying into that conversation. NCI notes what happens when the removed bladder is examined. People operated on for non-muscle-invasive disease are often found to have T2 or greater disease. The stage before surgery sometimes understates what is there.

Ask what urinary diversion would look like for you, and ask to speak with someone who has lived with the option being proposed.

For advanced or metastatic urothelial cancer, first-line treatment has changed recently. The EV-302 trial randomly assigned 886 people to enfortumab vedotin plus pembrolizumab, or to gemcitabine with cisplatin or carboplatin.

Median survival was 31.5 months with enfortumab vedotin plus pembrolizumab. It was 16.1 months with chemotherapy. Median progression-free survival was 12.5 months versus 6.3 months.

Side effects were lower overall in the newer arm. Grade 3 or higher events hit 55.9% versus 69.5%. But the pattern differed. On enfortumab vedotin plus pembrolizumab, the most common severe effects were skin reactions, nerve damage in the hands and feet, high blood sugar, and low white cells.

Ask whether that combination applies to your situation, and what monitoring goes with it. High blood sugar in particular is checked with blood tests rather than symptoms.

Repeat cystoscopy is uncomfortable and frequent, and the anxiety around each one is real and normal. Our page on fear of recurrence covers what helps.

Two other pages may help. For the difference between a tumor that returns nearby and one that shows up elsewhere, see local recurrence versus distant recurrence. For the disease itself, see bladder cancer.

• Call 911 or go to an emergency department if you cannot pass urine at all, or you are passing clots with heavy bleeding and severe pain.
• Call your care team the same day if a fever above 38.5°C (101.3°F) lasts more than two days after a BCG instillation, or if fever comes with shaking chills. BCG is a live organism, and a fever that will not settle can mean it has spread beyond the bladder. That is treated with anti-tuberculosis drugs, so it needs specialist input rather than waiting.
• A different rule applies during systemic treatment. Once enfortumab vedotin, chemotherapy or another marrow-suppressing drug is in the plan, any temperature of 38°C (100.4°F) or higher is a medical emergency in CDC's terms. Contact the team the moment it appears, day or night, and go to an emergency department if that call is not answered.
• Call your care team the same day if you are on enfortumab vedotin with pembrolizumab and a rash spreads, blisters or peels, or sores appear in the mouth, eyes or genitals. The label carries a boxed warning for severe and sometimes fatal skin reactions, and most of them appear during the first cycle.
• Call your care team the same day, and do not wait for the next appointment, if you are on enfortumab vedotin and feel very thirsty, are passing far more urine than usual, feel sick or short of breath, or your thinking turns fuzzy. The label carries a boxed warning for high blood sugar and diabetic ketoacidosis, which has been fatal, and it happens in people who have never had diabetes. If you cannot reach anyone quickly, or you are vomiting or drowsy, go to an emergency department.
• Call your care team within a day or two if blood or clots reappear in your urine between cystoscopies, or if passing urine burns and the urine is cloudy.

• National Cancer Institute, Bladder Cancer Treatment PDQ, health professional version, updated May 2, 2025; accessed August 6, 2026
• DailyMed, PADCEV (enfortumab vedotin-ejfv) prescribing information, accessed August 11, 2026
• Koya M, et al., Managing the adverse events of intravesical bacillus Calmette-Guérin therapy, PMC, accessed August 11, 2026
• MedlinePlus, Urine - bloody, accessed August 11, 2026